Santhera announces half-year 2024 results and provides corporate update

Ad hoc announcement pursuant to Art. 53 LR

A conference call will be held on September 12, 2024 at 2:30 p.m. CEST / 1:30 p.m. BST / 8:30 a.m. EDT. Details can be found at the end of this press release.

• Sales from contracts with customers of CHF 14.1 million (H1-2023: CHF 3.9 million)
• Operating result of CHF -17.7 million (H1-2023: CHF -20.3 million) and net result of
  CHF -15.3 million (H1-2023: CHF -23.3 million)
• AGAMREE (Vamorolone) was launched in Germany and Austria as the first European markets; the North American partner launched it in the USA
• AGAMREE approved in the UK for the treatment of Duchenne muscular dystrophy (DMD); New Drug Application (NDA) for DMD to be given priority review in China
• Cash and cash equivalents of CHF 16.5 million (June 30, 2024); complemented by a financing of up to CHF 69 million (closed in August 2024) to ensure financing until 2026, when a cash flow break-even is expected
• The business is now fully focused on commercialization in Europe and the further geographic expansion of AGAMREE in DMD

Pratteln, Switzerland, September 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2024, reports on progress with AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD), and provides updates on its corporate and financing initiatives.